Image-guided Microinvasive Percutaneous Treatment of Breast Lesions:                     Where Do We Stand?

Roknsharifi, Shima; Wattamwar, Kapil; Fishman, Michael; Ward, Robert C.; Ford, Kelly; Faintuch, Salomão; Joshi, Surekha; Dialani, Vandana

doi:10.1148/rg.2021200156

Cited by 29 publications

(39 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…VAE was approved by the FDA in 2002 for the removal of benign lesions and by the National Institute for Health and Care Excellence in the United Kingdom in 2006 [5]. However, it is still controversial for some high-risk lesions, such as phyllodes tumors or atypical lesions [5]. To date, several guidelines recommend VAE as an alternative to conventional open excision for benign breast lesions.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, it is needed to compare other minimally invasive procedures to remove breast mass. Recently, some procedures such as cryoablation, microwave ablation, highintensity focused ultrasonography, or laser therapy were introduced and some have shown promising results [5]. However, they have still limited evidence and only cryoablation and VAE have received FDA approval [5].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, some procedures such as cryoablation, microwave ablation, highintensity focused ultrasonography, or laser therapy were introduced and some have shown promising results [5]. However, they have still limited evidence and only cryoablation and VAE have received FDA approval [5]. In the future study, systematic review for these procedures would be needed.…”

Section: Discussionmentioning

confidence: 99%

“…Fine-needle aspiration and core needle biopsy cannot examine the whole mass, whereas VAE can perform a full examination of the entire mass. Owing to the advantage that VAE can remove the entire mass region, VAE has recently been widely used for both diagnostic and therapeutic purposes [3][4][5]. In 2002, the US Food and Drug Administration (FDA) approved VAE for the removal of benign lesions.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Safety of Vacuum-Assisted Excision for Benign Breast Mass Lesion: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background and Objective: Breast mass lesions are common; however, determining the malignant potential of the lesion can be ambiguous. Recently, to evaluate breast mass lesions, vacuum-assisted excision (VAE) biopsy has been widely used for both diagnostic and therapeutic purposes. This study aimed to investigate the therapeutic role of VAE. Materials and Methods: Relevant articles were obtained by searching PubMed and EMBASE on 3 September 2021. Meta-analyses were performed using odds ratios and proportions. To assess heterogeneity, we conducted a subgroup analysis and meta-regression tests. Results: Finally, 26 studies comprising 18,170 patients were included. All of these were observational studies. The meta-analysis showed that the complete resection rate of VAE was 0.930. In the meta-regression test, there was no significant difference. The meta-analysis showed a recurrence rate of 0.039 in the VAE group. The meta-regression test showed no statistical significance. Postoperative hematoma, pain, and ecchymosis after VAE were 0.092, 0.082, and 0.075, respectively. Conclusion: VAE for benign breast lesions showed favorable outcomes with respect to complete resection and complications. This meta-analysis suggested that VAE for low-risk benign breast lesions is a reasonable option for both diagnostic and therapeutic purposes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Vacuum-Assisted Excision for Benign Breast Mass Lesion: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, it is likely to evolve, so de‐escalation of treatments means that perhaps we can look to a future of minimal breast‐conserving surgery only for some patients, accurately predicting no need for more treatment. Trials of percutaneous outpatient surgery using, for example, cryoablation, radiofrequency, microwave or laser ablation, or vacuum‐assisted excision, are also promising 56 . For some tumours with specific mutations or immune environments, drug treatment alone may offer cure without the need for surgery.…”

Section: Future Possibilitiesmentioning

confidence: 99%